{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-061322","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.838461+00:00","generated_at":"2026-06-27T02:57:36.161442+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Lantheus appoints Minnie Baylor-Henry to Board of Directors","bullets":["Ms. Baylor-Henry, an expert in FDA regulatory affairs, appointed as Class II independent director effective March 1, 2022.","Will serve on the Compensation Committee and Science and Technology Committee.","Board now comprises nine directors, eight of whom are independent.","Compensation includes $55,000/yr cash, $25,833 initial RSU grant, and $155,000 annual RSU grant.","She previously served at FDA, Johnson & Johnson, and Deloitte; also on boards of APYX, PRTK, SCPH."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-061322","json":"https://secwatch.observer/filing/0001193125-22-061322.json","markdown":"https://secwatch.observer/filing/0001193125-22-061322.md","text":"https://secwatch.observer/filing/0001193125-22-061322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522061322/0001193125-22-061322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522061322/d299239d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:57:36.161442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca40129238","claim":"Minnie Baylor-Henry was appointed as Director at Lantheus Holdings, Inc..","evidence_excerpt":"On March 1, 2022, Lantheus Holdings, Inc. (“Lantheus”) appointed Ms. Minnie Baylor-Henry, a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’ Board of Directors (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522061322/0001193125-22-061322-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}